Published in J Carcinog on December 22, 2011
Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget (2017) 0.87
Oxidative stress specifically downregulates survivin to promote breast tumour formation. Br J Cancer (2013) 0.83
The BCL9-2 proto-oncogene governs estrogen receptor alpha expression in breast tumorigenesis. Oncotarget (2014) 0.83
Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse. Adv Exp Med Biol (2015) 0.83
Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients. Breast Cancer Res Treat (2013) 0.81
Genetically engineered ERα-positive breast cancer mouse models. Endocr Relat Cancer (2014) 0.77
Role of dietary bioactive natural products in estrogen receptor-positive breast cancer. Semin Cancer Biol (2016) 0.76
Mammary Ductal Environment Is Necessary for Faithful Maintenance of Estrogen Signaling in ER(+) Breast Cancer. Cancer Cell (2016) 0.75
Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells. Breast Cancer Res (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Molecular portraits of human breast tumours. Nature (2000) 94.14
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 25.54
Cancer cell cycles. Science (1996) 21.29
Tumor spectrum analysis in p53-mutant mice. Curr Biol (1994) 16.60
The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev (2000) 11.65
Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem (1994) 10.75
PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 9.94
Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell (1982) 9.29
Mammalian G1 cyclins. Cell (1993) 9.04
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (1997) 8.05
Specific protection against breast cancers by cyclin D1 ablation. Nature (2001) 6.94
Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell (1988) 6.48
Decision making by p53: life, death and cancer. Cell Death Differ (2003) 5.52
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (1994) 5.34
Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev (1993) 4.87
ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett (1996) 4.77
Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A (1987) 4.56
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst (2003) 4.45
Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci (2004) 4.40
TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell (1990) 3.86
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem (2001) 3.86
Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet (1993) 3.85
CDK-independent activation of estrogen receptor by cyclin D1. Cell (1997) 3.85
High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell (2004) 3.46
The ErbB receptors and their role in cancer progression. Exp Cell Res (2003) 3.37
Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab (2004) 3.10
Rescuing the function of mutant p53. Nat Rev Cancer (2001) 2.95
The role of prolactin in mammary carcinoma. Endocr Rev (2003) 2.95
Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev (2005) 2.87
Stem cells in the skin: waste not, Wnt not. Genes Dev (2003) 2.80
Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med (1995) 2.74
Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell (1990) 2.63
Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol (2009) 2.50
Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev (1995) 2.41
Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol (1997) 2.40
Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst (2009) 2.35
Menopause and breast cancer risk. J Natl Cancer Inst (1972) 2.27
Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. Development (2004) 2.24
Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett (2003) 2.22
Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev (1994) 2.08
The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res (2004) 2.04
A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene (2000) 2.03
Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A (2011) 2.01
Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene (2006) 1.77
New approaches to understanding p53 gene tumor mutation spectra. Mutat Res (1999) 1.75
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer (2005) 1.75
Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res (2004) 1.67
Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol (2008) 1.65
Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res (1999) 1.65
Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice. Mol Cell Biol (1992) 1.62
Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res (1995) 1.60
A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology (2000) 1.59
Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene (2003) 1.51
Atlas and histologic classification of tumors of the rat mammary gland. J Mammary Gland Biol Neoplasia (2000) 1.45
Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis. Oncogene (2007) 1.44
Biological and genetic properties of the p53 null preneoplastic mammary epithelium. FASEB J (2002) 1.42
Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors (2006) 1.40
Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer (2003) 1.35
Expression of prolactin and its receptor in human breast carcinoma. Endocrinology (1997) 1.32
Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab (1998) 1.31
Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther (2010) 1.30
Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy. Cancer Res (2006) 1.30
The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Res Treat (2009) 1.29
A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Cancer Res (1999) 1.27
Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res (2005) 1.26
Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer (1998) 1.25
Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene (2007) 1.24
Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res (2002) 1.21
G1 cyclin/cyclin-dependent kinase-coordinated phosphorylation of endogenous pocket proteins differentially regulates their interactions with E2F4 and E2F1 and gene expression. J Biol Chem (2002) 1.20
Hormone dependence in premalignant mammary progression. Cancer Res (2003) 1.16
Membrane initiated estrogen signaling in breast cancer. Biol Reprod (2006) 1.16
Mammary tumorigenesis in 7,12-dimethybenzanthracene-treated C57BL x DBA/2f F1 mice. Cancer Res (1980) 1.14
Reproductive role of prolactin. Reproduction (2007) 1.13
Molecular basis of pregnancy-induced breast cancer protection. Eur J Cancer Prev (2006) 1.12
Models of breast cancer: quo vadis, animal modeling? Breast Cancer Res (2003) 1.10
Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc Natl Acad Sci U S A (2010) 1.07
Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab (1997) 1.07
Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene (2005) 1.07
The MMTV LTR promoter is induced by progesterone and dihydrotestosterone but not by estrogen. Mol Endocrinol (1988) 1.03
Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis (2006) 1.03
Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. Am J Pathol (2003) 1.03
Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res (2001) 1.00
Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice. Mol Endocrinol (2004) 1.00
Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Res (2011) 0.99
Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice. Am J Pathol (2006) 0.98
The prolactin/growth hormone receptor family: structure/function relationships. J Mammary Gland Biol Neoplasia (1997) 0.98
Growth factors and their receptors in neoplastic mammary glands. Biomed Pharmacother (1995) 0.98
Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy. Breast Cancer Res Treat (2008) 0.96
Estrogen and progesterone receptors in cytology: a comprehensive review. Diagn Cytopathol (1992) 0.94
Accelerated onset of uterine tumors in transgenic mice with aberrant expression of the estrogen receptor after neonatal exposure to diethylstilbestrol. Mol Carcinog (1997) 0.94
Role of ERalpha in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesis. Carcinogenesis (2010) 0.94
Aberrant reproductive phenotypes evident in transgenic mice expressing the wild-type mouse estrogen receptor. Endocrinology (1994) 0.90
Conditional over-expression of estrogen receptor alpha in a transgenic mouse model. Transgenic Res (2002) 0.90
Estrogen receptor-positive mammary tumorigenesis in TGFalpha transgenic mice progresses with progesterone receptor loss. Oncogene (2007) 0.89
Mammary gland development and the prolactin receptor. Adv Exp Med Biol (2000) 0.88
P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Breast Cancer Res Treat (2010) 0.88
Moderate overexpression of AIB1 triggers pre-neoplastic changes in mammary epithelium. FEBS Lett (2006) 0.85
Breast cancer prevention in countries with diverse resources. Cancer (2008) 0.83
The genomic signature of breast cancer prevention. Recent Results Cancer Res (2007) 0.82
Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol (2003) 4.05
The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res (2002) 3.16
Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res (2006) 3.12
The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest (2009) 2.52
Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem (2003) 2.23
Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene (2004) 1.83
Centrobin: a novel daughter centriole-associated protein that is required for centriole duplication. J Cell Biol (2005) 1.73
Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways. Cancer Res (2007) 1.70
ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem (2003) 1.70
Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins. Mol Biol Cell (2006) 1.67
Shared as well as distinct roles of EHD proteins revealed by biochemical and functional comparisons in mammalian cells and C. elegans. BMC Cell Biol (2007) 1.58
The Cbl family and other ubiquitin ligases: destructive forces in control of antigen receptor signaling. Immunity (2004) 1.58
Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res (2007) 1.56
Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. Cancer Res (2007) 1.51
Negative regulation of Lck by Cbl ubiquitin ligase. Proc Natl Acad Sci U S A (2002) 1.40
Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. Biochim Biophys Acta (2012) 1.39
Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol Cell Biol (2002) 1.38
The carboxyl terminus of VEGFR-2 is required for PKC-mediated down-regulation. Mol Biol Cell (2005) 1.36
Src-like adaptor protein regulates TCR expression on thymocytes by linking the ubiquitin ligase c-Cbl to the TCR complex. Nat Immunol (2005) 1.35
The notch regulator MAML1 interacts with p53 and functions as a coactivator. J Biol Chem (2007) 1.33
Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator. J Biol Chem (2002) 1.32
Induction of cancer cell death by self-assembling nanostructures incorporating a cytotoxic peptide. Cancer Res (2010) 1.32
The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. J Leukoc Biol (2002) 1.32
Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther (2010) 1.30
TULA: an SH3- and UBA-containing protein that binds to c-Cbl and ubiquitin. Oncogene (2004) 1.30
Mammary epithelial cell transformation: insights from cell culture and mouse models. Breast Cancer Res (2005) 1.26
Tyrosine phosphorylation of Sprouty proteins regulates their ability to inhibit growth factor signaling: a dual feedback loop. Mol Biol Cell (2004) 1.24
A Wnt-CKIvarepsilon-Rap1 pathway regulates gastrulation by modulating SIPA1L1, a Rap GTPase activating protein. Dev Cell (2007) 1.22
Negative regulation of EphA2 receptor by Cbl. Biochem Biophys Res Commun (2002) 1.21
Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts. Cancer Res (2008) 1.20
Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci (2007) 1.17
CHIP and HSPs interact with beta-APP in a proteasome-dependent manner and influence Abeta metabolism. Hum Mol Genet (2007) 1.16
EH domain proteins regulate cardiac membrane protein targeting. Circ Res (2010) 1.15
Telomerase-immortalized human mammary stem/progenitor cells with ability to self-renew and differentiate. Proc Natl Acad Sci U S A (2010) 1.15
Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation. Biochem J (2006) 1.12
A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem (2006) 1.12
Tonic ubiquitylation controls T-cell receptor:CD3 complex expression during T-cell development. EMBO J (2010) 1.11
Ubiquitinylation of Ig beta dictates the endocytic fate of the B cell antigen receptor. J Immunol (2007) 1.09
A critical role for the E3-ligase activity of c-Cbl in VEGFR-2-mediated PLCgamma1 activation and angiogenesis. Proc Natl Acad Sci U S A (2007) 1.08
An essential role of human Ada3 in p53 acetylation. J Biol Chem (2007) 1.07
Endosomal-sorting complexes required for transport (ESCRT) pathway-dependent endosomal traffic regulates the localization of active Src at focal adhesions. Proc Natl Acad Sci U S A (2010) 1.07
Overexpression of RhoA induces preneoplastic transformation of primary mammary epithelial cells. Cancer Res (2009) 1.06
Endocytic recycling proteins EHD1 and EHD2 interact with fer-1-like-5 (Fer1L5) and mediate myoblast fusion. J Biol Chem (2010) 1.05
Constitutive endocytosis and degradation of the pre-T cell receptor. J Exp Med (2002) 1.05
A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther (2008) 1.04
Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci (2010) 1.04
Mammalian alteration/deficiency in activation 3 (Ada3) is essential for embryonic development and cell cycle progression. J Biol Chem (2012) 1.03
The endocytic recycling regulator EHD1 is essential for spermatogenesis and male fertility in mice. BMC Dev Biol (2010) 1.03
Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src. BMC Cell Biol (2009) 1.03
Alteration/deficiency in activation-3 (Ada3) plays a critical role in maintaining genomic stability. Cell Cycle (2012) 1.03
Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast. Life Sci (2008) 1.03
Differential regulation of EHD3 in human and mammalian heart failure. J Mol Cell Cardiol (2012) 1.02
Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. Oncotarget (2011) 1.01
Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived growth factor receptor beta provides a dual mechanism of negative regulation. J Biol Chem (2007) 1.01
Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells. Proc Natl Acad Sci U S A (2010) 1.01
Human ADA3 binds to estrogen receptor (ER) and functions as a coactivator for ER-mediated transactivation. J Biol Chem (2004) 1.01
Ada3 requirement for HAT recruitment to estrogen receptors and estrogen-dependent breast cancer cell proliferation. Cancer Res (2007) 1.00
EHD4 and CDH23 are interacting partners in cochlear hair cells. J Biol Chem (2009) 1.00
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther (2011) 1.00
Human papillomavirus E6-induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase. Cancer Res (2002) 0.99
Renal thrombotic microangiopathy in mice with combined deletion of endocytic recycling regulators EHD3 and EHD4. PLoS One (2011) 0.99
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med (2009) 0.99
Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients. Epigenetics (2006) 0.97
Cbl-mediated ubiquitinylation and negative regulation of Vav. J Biol Chem (2003) 0.97
The human orthologue of Drosophila ecdysoneless protein interacts with p53 and regulates its function. Cancer Res (2006) 0.96
Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients. Cell Oncol (2009) 0.96